BridgeMD
New treatment option for Suicidal Ideation
Official title Stratified-Care School-Based Intervention for Adolescent Suicidal Ideation
ClinicalTrials.gov ID: NCT07063914
What this study is testing
- What it's testing
- Background. Suicidal ideation and depressive symptoms are highly prevalent among adolescents, with suicide representing a leading cause of death in this age group worldwide.
- Which group you join is decided by chance.
A plain-language read of the study's public ClinicalTrials.gov listing. The study team confirms the details.
Who can take part
Ages 14 to 18
You may be able to join if
- for Educational Institutions
- Located in Santiago, Chile.
- Secondary education level (grades I-IV Medio).
- Coeducational schools.
- At least two classes per grade level in secondary education.
You likely can't join if
- Exclusion Criteria for Students
- Participation in a structured suicide prevention program (Reframe-IT+) during 2024.
- Severe psychotic symptoms, such as perceptual disturbances or delusional ideas, assessed during the eligibility interview.
- Suicide attempt(s) in the past three months, assessed during the eligibility interview.
See the full eligibility criteria
- for Educational Institutions
- Located in Santiago, Chile.
- Secondary education level (grades I-IV Medio).
- Coeducational schools.
- At least two classes per grade level in secondary education.
- A minimum of 30 students per class.
- Socioeconomic vulnerability level of ≥ 50%, as measured by the School Vulnerability Index (Índice de Vulnerabilidad Escolar - IVE-SINAE), which includes factors such as parental education and total household income. for...
- Enrolled in grades I, II, or III Medio.
- Suicidal ideation within the past month, defined as a score ≥ 3 on the Columbia-Suicide Severity Rating Scale (C-SSRS).
- For the Reframe-IT+ program: mild or moderate depressive symptoms, defined as a PHQ-9 score \< 20.
- For the CARIBOU program: severe depressive symptoms, defined as a PHQ-9 score ≥ 20.
- Exclusion Criteria for Students
- Participation in a structured suicide prevention program (Reframe-IT+) during 2024.
- Severe psychotic symptoms, such as perceptual disturbances or delusional ideas, assessed during the eligibility interview.
- Suicide attempt(s) in the past three months, assessed during the eligibility interview.
The study team makes the final eligibility decision.
Where it's taking place
- Santiago, Las Condes, Chile
Questions & answers
Do participants get paid in this trial?
This listing doesn't specify compensation. Many trials still reimburse travel or offer a stipend, so it's worth asking the study team when you connect.
Is it free to join, and do I need insurance?
Searching and applying through BridgeMD is free. In clinical trials the study-related treatment and visits are generally provided at no cost to you. You usually don't need insurance to take part - confirm specifics with the study team.
How long does this study last?
The listing doesn't state an exact length. The study team walks you through the schedule and number of visits before you decide to enroll.
Who can join this trial?
This study is enrolling all sexes, 14 years to 18 years. The study team makes the final eligibility decision.
Where is this trial taking place?
Study sites include Santiago, Las Condes, Chile. Enter your location above to see the nearest site and check your eligibility.
Explore other conditions
BridgeMD is an information and trial-matching tool - not medical advice, and not the study sponsor. Details come from ClinicalTrials.gov; the study team decides eligibility.